DXS International's Annual Results Overview
DXS INTERNATIONAL PLC
(AQSE: DXSP)
ANNUAL RESULTS
The Board of DXS International plc, a company listed on the AQSE Growth Market known for its groundbreaking healthcare information and digital clinical decision support systems, is excited to unveil its audited financial results for the fiscal year ending 30 April 2025.
Financial Highlights
Key Financial Metrics:
- Revenue has risen by 5% to £3,469,917 from last year's £3,308,359.
- The core recurring revenue model has exhibited remarkable resilience.
- At the close of the period, available cash stood at £428,957, complemented by unutilised debtor drawdowns amounting to £245,043.
- The net loss for the year totaled £94,750, a significant improvement from last year's loss of £4,738,686, impacted by increased amortisation and an impairment charge.
Operational Highlights
Innovative Developments: SMART Referrals
The recent launch of our customer-focused SMART Referral system is a significant milestone, currently being tested in select GP practices. This new solution is set to replace the existing DXS Point of Care solution and is anticipated to drive substantial growth, especially with the expected revival of NHS funding in April 2026.
Improvements in Secondary Care
Our customised SMART Referral solution continues to demonstrate success in reducing patient wait times. Additionally, we are testing new functionalities aimed at seamlessly integrating referral data into specialized unit systems, eliminating manual efforts, and enhancing overall efficiency.
ExpertCare in Medicine Optimisation
Our ExpertCare Medicine Optimisation solution has proven to be highly effective, having recently undergone an 18-month assessment funded by Innovate UK, in collaboration with notable institutions. The study highlighted exceptional ROI for the NHS regarding hypertension management, further supplemented by a new Cholesterol Module to enhance the solution.
Looking Ahead: Optimism for Future Growth
As the NHS grapples with the challenge of reducing wait times while addressing cardiovascular disease (CVD) issues, there is increased pressure for digital innovation in healthcare. The NHS's Ten-Year Digital Transformation Plan emphasizes technology-driven healthcare solutions, directing funding to initiatives yielding high impact.
Chief Executive David Immelman noted, "Despite the frustrations associated with delayed revenue growth, we observe promising signals indicating that the NHS is reopening channels for investment in digital solutions to tackle its current challenges. At DXS, our team remains dedicated to pursuing opportunities to enhance value for our shareholders by providing solutions with clear return on investment (ROI) for the NHS."
Director's Report
The Directors of DXS pride themselves on presenting comprehensive updates on the company’s achievements, trading performance, and strategic direction. For the year ending 30 April 2025, we recorded a 5% increase in turnover, a promising indicator of our operational discipline and improving financials.
Looking to the Future
With strong foundations in place, we aim to foster positive momentum moving forward. We will continue to innovate and develop unique NHS solutions that can improve health outcomes for patients across the board.
Frequently Asked Questions
What are the main highlights from DXS International's financial report?
The financial report highlighted a 5% increase in revenue, improved loss figures, robust operational developments, and exciting future prospects.
How does DXS plan to address the challenges faced by the NHS?
DXS aims to provide digital solutions that meet the needs of the NHS, focusing on cutting-edge technology to enhance patient care while addressing operational efficiency.
What progress has been made with the SMART Referral system?
The SMART Referral system is currently being tested in select GP practices, and it’s projected to replace previous solutions and drive significant revenue growth.
How does DXS International contribute to medication optimisation?
Through its ExpertCare solution, DXS optimises medicine management, having shown exceptional ROI in hypertension treatment, demonstrating a commitment to patient care.
What are the future strategies for revenue growth?
DXS plans to leverage NHS funding renewals, explore international markets for its solutions, and continue investing in innovation to enhance its product offerings.
